The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Retinoic Acid and Arsenic Synergize to Eradicate Leukemic Cells in a Mouse Model of Acute Promyelocytic Leukemia
Open accessAbstract
In acute promyelocytic leukemia (APL) patients, retinoic acid (RA) triggers differentiation while arsenic trioxide (arsenic) induces both a partial differentiation and apoptosis. Although their mechanisms of action are believed to be distinct, these two drugs both induce the catabolism of the oncogenic promyelocytic leukemia (PML)/RARα fusion protein. While APL cell lines resistant to one agent are sensitive to the other, the benefit of combining RA and arsenic in cell culture is controversial, and thus far, no data are available in patients. Using syngenic grafts of leukemic blasts from PML/RARα transgenic mice as a model for APL, we demonstrate that arsenic induces apoptosis and modest differentiation, and prolongs mouse survival. Furthermore, combining arsenic with RA accelerates tumor regression through enhanced differentiation and apoptosis. Although RA or arsenic alone only prolongs survival two- to threefold, associating the two drugs leads to tumor clearance after a 9-mo relapse-free period. These studies establishing RA/arsenic synergy in vivo prompt the use of combined arsenic/RA treatments in APL patients and exemplify how mouse models of human leukemia can be used to design or optimize therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
Huang, M., Ye, Y., Chen, Sr., Chai, Jr., Lu, J., Zhoa, L., Gu, L., & Wang, Z. (1988) · Blood · doi:10.1182/blood.v72.2.567.567 · Cited by 2,445
Shen, Z.-X., Chen, G.-Q., Ni, J.-H., Li, X.-S., Xiong, S.-M., Qiu, Q.-Y., Zhu, J., Tang, W., Sun, G.-L., Yang, K.-Q., et al. (1997) · Blood · doi:10.1182/blood.v89.9.3354 · Cited by 1,428
Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide
Soignet, S. L., Maslak, P., Wang, Z.-G., Jhanwar, S., Calleja, E., Dardashti, L. J., Corso, D., DeBlasio, A., Gabrilove, J., Scheinberg, D. A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391901 · Cited by 1,213
Role of the histone deacetylase complex in acute promyelocytic leukaemia
Lin, R. J., Nagy, L., Inoue, S., Shao, W., Miller, W. H., & Evans, R. M. (1998) · Nature · doi:10.1038/35895 · Cited by 1,062
Grignani, F., De Matteis, S., Nervi, C., Tomassoni, L., Gelmetti, V., Cioce, M., Fanelli, M., Ruthardt, M., Ferrara, F. F., Zamir, I., et al. (1998) · Nature · doi:10.1038/35901 · Cited by 1,004
Structure and Function in the Nucleus
Lamond, A. I., & Earnshaw, W. C. (1998) · Science · doi:10.1126/science.280.5363.547 · Cited by 923
Chen, G., Zhu, J., Shi, X., Ni, J., Zhong, H., Si, G., Jin, X., Tang, W., Li, X., Xong, S., et al. (1996) · Blood · doi:10.1182/blood.v88.3.1052.1052 · Cited by 864
A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein
Dyck, J. A., Maul, G. G., Miller, W. H., Chen, J. D., Kakizuka, A., & Evans, R. M. (1994) · Cell · doi:10.1016/0092-8674(94)90340-9 · Cited by 785
Chen, G., Shi, X., Tang, W., Xiong, S. M., Zhu, J., Cai, X., Han, Z., Ni, J.-H., Shi, G., Jia, P.-M., et al. (1997) · PubMed · Cited by 781
Warrell, R. P., de The, H., Wang, Z.-Y., & Degos, L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307153290307 · Cited by 776
Self-citationHe, L.-Z., Figueiredo-Pontes, L. L., Rego, E. M., & Pandolfi, P. P. (2015) · Encyclopedia of Cancer · doi:10.1007/978-3-662-46875-3_63 · Cited by 766
Muller, S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.1.61 · Cited by 674
Weis, K., Rambaud, S., Lavau, C., Jansen, J., Carvalho, T., Carmo-Fonseca, M., Lamond, A., & Dejean, A. (1994) · Cell · doi:10.1016/0092-8674(94)90341-7 · Cited by 652
Grignani, F., Ferrucci, P. F., Testa, U., Talamo, G., Fagioli, M., Alcalay, M., Mencarelli, A., Grignani, F., Peschle, C., Nicoletti, I., et al. (1993) · Cell · doi:10.1016/0092-8674(93)80044-f · Cited by 583
Role of PML in Cell Growth and the Retinoic Acid Pathway
Gang Wang, Z., Delva, L., Gaboli, M., Rivi, R., Giorgio, M., Cordon-Cardo, C., Grosveld, F., & Paolo Pandolfi, P. (1998) · Science · doi:10.1126/science.279.5356.1547 · Cited by 517
The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion.
Koken, M. H., Puvion-Dutilleul, F., Guillemin, M. C., Viron, A., Linares-Cruz, G., Stuurman, N., de Jong, L., Szostecki, C., Calvo, F., & Chomienne, C. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06356.x · Cited by 499
Self-citationMelcher, A., Todryk, S., Hardwick, N., Ford, M., Jacobson, M., & Vile, R. G. (1998) · Nature Medicine · doi:10.1038/nm0598-581 · Cited by 445
A PMLRAR α transgene initiates murine acute promyelocytic leukemia
Brown, D., Kogan, S., Lagasse, E., Weissman, I., Alcalay, M., Pelicci, P. G., Atwater, S., & Bishop, J. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2551 · Cited by 434
Self-citationZhu, J., Koken, M. H. M., Quignon, F., Chelbi-Alix, M. K., Degos, L., Wang, Z. Y., Chen, Z., & de Thé, H. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3978 · Cited by 427
Self-citationPML induces a novel caspase-independent death process
Quignon, F., De Bels, F., Koken, M., Feunteun, J., Ameisen, J.-C., & de Thé, H. (1998) · Nature Genetics · doi:10.1038/3068 · Cited by 374
Self-citationDegos, L., Dombret, H., Chomienne, C., Daniel, M., Miclea, J., Chastang, C., Castaigne, S., & Fenaux, P. (1995) · Blood · doi:10.1182/blood.v85.10.2643.bloodjournal85102643 · Cited by 362
Self-citationShao, W., Fanelli, M., Ferrara, F. F., Riccioni, R., Rosenauer, A., Davison, K., Lamph, W. W., Waxman, S., Pelicci, P. G., Lo Coco, F., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.2.124 · Cited by 344
Rochette-Egly, C., Adam, S., Rossignol, M., Egly, J.-M., & Chambon, P. (1997) · Cell · doi:10.1016/s0092-8674(00)80317-7 · Cited by 308
PML, a growth suppressor disrupted in acute promyelocytic leukemia.
Mu, Z. M., Chin, K. V., Liu, J. H., Lozano, G., & Chang, K. S. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.10.6858 · Cited by 288
PML protein expression in hematopoietic and acute promyelocytic leukemia cells
Daniel, M., Koken, M., Romagne, O., Barbey, S., Bazarbachi, A., Stadler, M., Guillemin, M., Degos, L., Chomienne, C., & de The, H. (1993) · Blood · doi:10.1182/blood.v82.6.1858.1858 · Cited by 251
Self-citationYoshida, H., Kitamura, K., Tanaka, K., Ōmura, S., Miyazaki, T., Hachiya, T., Ohno, R., & Naoe, T. (1996) · PubMed · Cited by 249
The PML growth-suppressor has an altered expression in human oncogenesis.
Koken, M. H. M., Linares‐Cruz, G., Quignon, F., Viron, A., Chelbi‐Alix, M. K., Sobczak‐Thépot, J., Juhlin, L., Degos, L., Calvo, F. M., & de Thé, H. (1995) · PubMed · Cited by 231
Self-citationTsai, S., & Collins, S. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.15.7153 · Cited by 210
Raelson, J., Nervi, C., Rosenauer, A., Benedetti, L., Monczak, Y., Pearson, M., Pelicci, P., & Miller, W. J. (1996) · Blood · doi:10.1182/blood.v88.8.2826.bloodjournal8882826 · Cited by 197
Giannı̀, M., Koken, M. H. M., Chelbi-Alix, M. K., Benoit, G., Lanotte, M., Chen, Z., & de Thé, H. (1998) · Blood · doi:10.1182/blood.v91.11.4300 · Cited by 164
Analysis of the Growth and Transformation Suppressor Domains of Promyelocytic Leukemia Gene, PML
Le, X., Yang, P., & Chang, K.-S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.1.130 · Cited by 126
Lichtman, M. A., Spivak, J., Boxer, L. A., Shattil, S. J., & Henderson, E. S. (2000) · Elsevier eBooks · doi:10.1016/b978-012448510-5/50163-1 · Cited by 116
Taneja, R., Rochette‐Egly, C., Plassat, J., Penna, L., Gaub, M., & Chambon, P. (1997) · The EMBO Journal · doi:10.1093/emboj/16.21.6452 · Cited by 113
Labrecque, J., Allan, D., Chambon, P., Iscove, N. N., Lohnes, D., & Hoang, T. (1998) · Blood · doi:10.1182/blood.v92.2.607 · Cited by 107
Castaigné, S., Balitrand, N., de Thé, H., Dejean, A., Degos, L., & Chomienne, C. (1992) · Blood · doi:10.1182/blood.v79.12.3110.3110 · Cited by 101
Self-citationLe, X., Vallian, S., Mu, Z.-M., Hung, M., & Chang, K.-S. (1998) · Oncogene · doi:10.1038/sj.onc.1201705 · Cited by 98
Nason-Burchenal, K., Gandini, D., Botto, M., et al. (1996) · Blood · doi:10.1182/blood.v88.10.3926.bloodjournal88103926 · Cited by 63
Retinoic acid and arsenic: towards oncogene-targeted treatments of acute promyelocytic leukaemia
Quignon, F., Chen, Z., & de Thé, H. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00025-5 · Cited by 41
Cited by
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300874 · Cited by 1,611
Acute promyelocytic leukemia: from highly fatal to highly curable
Wang, Z.-Y., & Chen, Z. (2008) · Blood · doi:10.1182/blood-2007-07-102798 · Cited by 1,277
Maximizing mouse cancer models
Frese, K. K., & Tuveson, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2192 · Cited by 717
Shen, Z.-X., Shi, Z.-Z., Fang, J., Gu, B.-W., Li, J.-M., Zhu, Y.-M., Shi, J.-Y., Zheng, P.-Z., Yan, H., Liu, Y.-F., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400053101 · Cited by 583
Self-citationPML targeting eradicates quiescent leukaemia-initiating cells
Ito, K., Bernardi, R., Morotti, A., Matsuoka, S., Saglio, G., Ikeda, Y., Rosenblatt, J., Avigan, D. E., Teruya-Feldstein, J., & Pandolfi, P. P. (2008) · Nature · doi:10.1038/nature07016 · Cited by 538
Metadata
- Authors
- Lallemand-Breitenbach, V., Guillemin, M.-C., Janin, A., Daniel, M.-T., Degos, L., Kogan, S. C., Michael Bishop, J., & de Thé, H.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 1999-04-05
- Volume
- 189
- Issue
- 7
- Pages
- 1043-1052
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2108362314
- Cited by
- 305
- References
- 38
- FWCI
- 6.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.